37
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Lack of beta-arrestin signaling in the absence of active G proteins

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          G protein-independent, arrestin-dependent signaling is a paradigm that broadens the signaling scope of G protein-coupled receptors (GPCRs) beyond G proteins for numerous biological processes. However, arrestin signaling in the collective absence of functional G proteins has never been demonstrated. Here we achieve a state of “zero functional G” at the cellular level using HEK293 cells depleted by CRISPR/Cas9 technology of the Gs/q/12 families of Gα proteins, along with pertussis toxin-mediated inactivation of Gi/o. Together with HEK293 cells lacking β-arrestins (“zero arrestin”), we systematically dissect G protein- from arrestin-driven signaling outcomes for a broad set of GPCRs. We use biochemical, biophysical, label-free whole-cell biosensing and ERK phosphorylation to identify four salient features for all receptors at “zero functional G”: arrestin recruitment and internalization, but—unexpectedly—complete failure to activate ERK and whole-cell responses. These findings change our understanding of how GPCRs function and in particular of how they activate ERK1/2.

          Abstract

          Arrestins terminate signaling from GPCRs, but several lines of evidence suggest that they are also able to transduce signals independently of G proteins. Here, the authors systematically ablate G proteins in cell lines, and show that arrestins are unable to act as genuine signal initiators.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: found
          • Article: not found

          Teaching old receptors new tricks: biasing seven-transmembrane receptors.

          Seven-transmembrane receptors (7TMRs; also known as G protein-coupled receptors) are the largest class of receptors in the human genome and are common targets for therapeutics. Originally identified as mediators of 7TMR desensitization, beta-arrestins (arrestin 2 and arrestin 3) are now recognized as true adaptor proteins that transduce signals to multiple effector pathways. Signalling that is mediated by beta-arrestins has distinct biochemical and functional consequences from those mediated by G proteins, and several biased ligands and receptors have been identified that preferentially signal through either G protein- or beta-arrestin-mediated pathways. These ligands are not only useful tools for investigating the biochemistry of 7TMR signalling, they also have the potential to be developed into new classes of therapeutics.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling.

            For many years, beta-adrenergic receptor antagonists (beta-blockers or betaAR antagonists) have provided significant morbidity and mortality benefits in patients who have sustained acute myocardial infarction. More recently, beta-adrenergic receptor antagonists have been found to provide survival benefits in patients suffering from heart failure, although the efficacy of different beta-blockers varies widely in this condition. One drug, carvedilol, a nonsubtype-selective betaAR antagonist, has proven particularly effective in the treatment of heart failure, although the mechanism(s) responsible for this are controversial. Here, we report that among 16 clinically relevant betaAR antagonists, carvedilol displays a unique profile of in vitro signaling characteristics. We observed that in beta2 adrenergic receptor (beta2AR)-expressing HEK-293 cells, carvedilol has inverse efficacy for stimulating G(s)-dependent adenylyl cyclase but, nonetheless, stimulates (i) phosphorylation of the receptor's cytoplasmic tail on previously documented G protein-coupled receptor kinase sites; (ii) recruitment of beta-arrestin to the beta2AR; (iii) receptor internalization; and (iv) activation of extracellular regulated kinase 1/2 (ERK 1/2), which is maintained in the G protein-uncoupled mutant beta2AR(T68F,Y132G,Y219A) (beta2AR(TYY)) and abolished by beta-arrestin2 siRNA. Taken together, these data indicate that carvedilol is able to stabilize a receptor conformation which, although uncoupled from G(s), is nonetheless able to stimulate beta-arrestin-mediated signaling. We hypothesize that such signaling may contribute to the special efficacy of carvedilol in the treatment of heart failure and may serve as a prototype for a new generation of therapeutic beta2AR ligands.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Role of beta-arrestin in mediating agonist-promoted G protein-coupled receptor internalization.

              beta-Arrestins are proteins that bind phosphorylated heterotrimeric GTP-binding protein (G protein)-coupled receptors (GPCRs) and contribute to the desensitization of GPCRs by uncoupling the signal transduction process. Resensitization of GPCR responsiveness involves agonist-mediated receptor sequestration. Overexpression of beta-arrestins in human embryonic kidney cells rescued the sequestration of beta 2-adrenergic receptor (beta 2AR) mutants defective in their ability to sequester, an effect enhanced by simultaneous overexpression of beta-adrenergic receptor kinase 1. Wild-type beta 2AR sequestration was inhibited by the overexpression of two beta-arrestin mutants. These findings suggest that beta-arrestins play an integral role in GPCR internalization and thus serve a dual role in the regulation of GPCR function.
                Bookmark

                Author and article information

                Contributors
                kostenis@uni-bonn.de
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                23 January 2018
                23 January 2018
                2018
                : 9
                : 341
                Affiliations
                [1 ]ISNI 0000 0001 2240 3300, GRID grid.10388.32, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, University of Bonn, ; Nussallee 6, 53115 Bonn, Germany
                [2 ]ISNI 0000 0001 2248 6943, GRID grid.69566.3a, Graduate School of Pharmaceutical Science, , Tohoku University, ; Sendai, 980-8578 Japan
                [3 ]ISNI 0000 0004 1754 9200, GRID grid.419082.6, PRESTO, Japan Science and Technology Agency (JST), ; 4-1-8, Honcho, Kawaguchi, 332-0012 Japan
                [4 ]ISNI 0000 0000 8517 6224, GRID grid.275559.9, Institute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, , University Hospital Jena, ; Hans-Knöll-Strasse2, 07745 Jena, Germany
                [5 ]ISNI 0000 0001 1958 8658, GRID grid.8379.5, Bio-Imaging-Center/Rudolf-Virchow-Center, Institute of Pharmacology, , University of Wuerzburg, ; Versbacher Str. 9, 97078 Würzburg, Germany
                [6 ]ISNI 0000 0001 2240 3300, GRID grid.10388.32, Institute for Pharmaceutical Biology, , University of Bonn, ; Nussallee 6, 53115 Bonn, Germany
                [7 ]ISNI 0000 0001 2240 3300, GRID grid.10388.32, Pharmaceutical Biochemistry and Bioanalytics, Institute of Pharmacy, , University of Bonn, ; An der Immenburg 4, 53121 Bonn, Germany
                [8 ]ISNI 0000 0004 5373 4593, GRID grid.480536.c, AMED-CREST, , Japan Agency for Medical Research and Development, ; 1-7-1 Otemachi, Tokyo, 100-0004 Japan
                [9 ]ISNI 0000 0001 2203 7304, GRID grid.419635.c, Molecular Signaling Section, , Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), ; Bethesda, MD 20892 USA
                Author information
                http://orcid.org/0000-0003-4163-7334
                Article
                2661
                10.1038/s41467-017-02661-3
                5780443
                29362459
                3425977d-28fc-46a7-9d98-0f74cfe6ce2e
                © The Author(s) 2018

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 14 July 2017
                : 18 December 2017
                Categories
                Article
                Custom metadata
                © The Author(s) 2018

                Uncategorized
                Uncategorized

                Comments

                Comment on this article